Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DCL000171

Drug Information
IndicationSolid Tumors
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Phase I    

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESC1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 850879-09-3
PubChem Compound IDCID 11282283.
TargetC-Met receptor tyrosine kinaseInhibitor[1]
C-Met receptor tyrosine kinaseMultitarget[1]
Platelet-derived growth factor receptorInhibitor[1]
Platelet-derived growth factor receptorMultitarget[1]
Proto-oncogene tyrosine-protein kinase KitInhibitor[1]
Proto-oncogene tyrosine-protein kinase KitMultitarget[1]
Ref 1MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer. 2009 May 11;9:142. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543